SHANGHAI – Jiangsu Nhwa Pharmaceutical Co. Ltd.'s DP-VPA, a modified valproic acid (VPA) treatment for epilepsy, has received fast track status from the CFDA. The drug was first licensed from D-Pharm Ltd., of Rehovot, Israel, in 2011 and holds promise for its targeted technology to be more potent and safer than other forms of VPA, the leading therapy for seizures.